Osimertinib mesylate (CAS: 1421373-66-1) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved by the FDA for the treatment of non-small cell lung cancer (NSCLC). It is designed to target specific mutations in the EGFR gene, which are present in a subset of NSCLC patients and can lead to more aggressive forms of the disease.
Chemical name:
The chemical name of Osimertinib mesylate is methyl (2E)-2-[6-[2-(dimethylamino)ethyl]oxy]-4-(4-{[4-methyl-6-(4-quinolinyl)-2-pyrimidinyl]amino}-2-propenoyl)phenyl]ethanesulfonate.
Molecular formula:
The molecular formula of Osimertinib mesylate is C28H33N7O3S.
Formula weight:
The formula weight of Osimertinib mesylate is 581.68 g/mol.
CAS No:
The CAS number of Osimertinib mesylate is 1421373-66-1.
Top ten keywords from Google and Synonyms:
Health benefits of this product:
Osimertinib mesylate is designed to target specific mutations in the EGFR gene that are present in a subset of NSCLC patients. By inhibiting the activity of this gene, Osimertinib mesylate can reduce the growth and spread of cancer cells, potentially leading to improved outcomes for patients with NSCLC.
Potential effects:
Clinical trials have shown that Osimertinib mesylate is effective in treating NSCLC patients with certain mutations in the EGFR gene, particularly the T790M mutation, which is associated with resistance to other therapies. Osimertinib mesylate has also been shown to have fewer side effects than other EGFR TKIs, such as erlotinib or gefitinib.
Product mechanism:
Osimertinib mesylate works by inhibiting the activity of the EGFR protein, which is involved in cell growth and proliferation. In patients with NSCLC, mutations in the EGFR gene can lead to overactivity of the protein, leading to the growth and spread of cancer cells. Osimertinib mesylate selectively targets these mutations, reducing the activity of the protein and slowing the growth of cancer cells.
Safety:
The safety of Osimertinib mesylate has been established in clinical trials. However, like all medications, there may be side effects, and it should only be used under the supervision of a healthcare professional.
Side effects:
The most common side effects of Osimertinib mesylate include diarrhea, rash, and dry skin. Less common side effects include interstitial lung disease, QT prolongation, and visual disturbances.
Dosing information:
The dosing of Osimertinib mesylate will depend on various factors, including the type and stage of cancer being treated, the patient's overall health, and other medications being used. The recommended dosing and treatment duration will be determined by a healthcare professional.
Conclusion:
Osimertinib mesylate (CAS: 1421373-66-1) is a third-generation EGFR TKI that has been approved by the FDA for the treatment of NSCLC. Its mechanism of action makes it a targeted therapy that can improve outcomes for patients with NSCLC who have certain mutations in the EGFR gene. While its safety has been established in clinical trials, there may be side effects, and dosing should be determined by a healthcare professional. Overall, Osimertinib mesylate represents an exciting new avenue for targeted cancer therapy, and further research is needed to establish its full potential as a treatment option for NSCLC patients.
